James S. Norris

Title
InstitutionMedical University of South Carolina
DepartmentMicrobiology and Immunology
AddressP.O. Box MSC 504
HCC 310
86 Jonathan Lucas St.
Phone843-792-7915
Fax843-792-4882
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Zhao D, Hajiaghamohseni LM, Liu X, Szulc ZM, Bai A, Bielawska A, Norris JS, Reddy SV, Hannun YA, Haque A. Inhibition of acid ceramidase regulates MHC class II antigen presentation and suppression of autoimmune arthritis. Cytokine. 2020 11; 135:155219. PMID: 32738771.
      Citations:    
    2. White-Gilbertson S, Lu P, Jones CM, Chiodini S, Hurley D, Das A, Delaney JR, Norris JS, Voelkel-Johnson C. Tamoxifen is a candidate first-in-class inhibitor of acid ceramidase that reduces amitotic division in polyploid giant cancer cells-Unrecognized players in tumorigenesis. Cancer Med. 2020 05; 9(9):3142-3152. PMID: 32135040.
      Citations:    
    3. White-Gilbertson S, Lu P, Norris JS, Voelkel-Johnson C. Genetic and pharmacological inhibition of acid ceramidase prevents asymmetric cell division by neosis. J Lipid Res. 2019 07; 60(7):1225-1235. PMID: 30988134.
      Citations:    
    4. Voelkel-Johnson C, Norris JS, White-Gilbertson S. Interdiction of Sphingolipid Metabolism Revisited: Focus on Prostate Cancer. Adv Cancer Res. 2018; 140:265-293. PMID: 30060812.
      Citations:    
    5. Kim S, Alsaidan OA, Goodwin O, Li Q, Sulejmani E, Han Z, Bai A, Albers T, Beharry Z, Zheng YG, Norris JS, Szulc ZM, Bielawska A, Lebedyeva I, Pegan SD, Cai H. Blocking Myristoylation of Src Inhibits Its Kinase Activity and Suppresses Prostate Cancer Progression. Cancer Res. 2017 12 15; 77(24):6950-6962. PMID: 29038344.
      Citations:    
    6. Dworski S, Lu P, Khan A, Maranda B, Mitchell JJ, Parini R, Di Rocco M, Hugle B, Yoshimitsu M, Magnusson B, Makay B, Arslan N, Guelbert N, Ehlert K, Jarisch A, Gardner-Medwin J, Dagher R, Terreri MT, Lorenco CM, Barillas-Arias L, Tanpaiboon P, Solyom A, Norris JS, He X, Schuchman EH, Levade T, Medin JA. Acid Ceramidase Deficiency is characterized by a unique plasma cytokine and ceramide profile that is altered by therapy. Biochim Biophys Acta Mol Basis Dis. 2017 02; 1863(2):386-394. PMID: 27915031.
      Citations:    
    7. Price ST, Beckham TH, Cheng JC, Lu P, Liu X, Norris JS. Sphingosine 1-Phosphate Receptor 2 Regulates the Migration, Proliferation, and Differentiation of Mesenchymal Stem Cells. Int J Stem Cell Res Ther. 2015; 2(2). PMID: 27275017.
      Citations:    
    8. Jones EE, Gao P, Smith CD, Norris JS, Drake RR. Tissue biomarkers of drug efficacy: case studies using a MALDI-MSI workflow. Bioanalysis. 2015; 7(20):2611-9. PMID: 26505686.
      Citations:    
    9. Beckham TH, Cheng JC, Lu P, Marrison ST, Norris JS, Liu X. Acid ceramidase promotes nuclear export of PTEN through sphingosine 1-phosphate mediated Akt signaling. PLoS One. 2013; 8(10):e76593. PMID: 24098536.
      Citations:    
    10. Cheng JC, Bai A, Beckham TH, Marrison ST, Yount CL, Young K, Lu P, Bartlett AM, Wu BX, Keane BJ, Armeson KE, Marshall DT, Keane TE, Smith MT, Jones EE, Drake RR, Bielawska A, Norris JS, Liu X. Radiation-induced acid ceramidase confers prostate cancer resistance and tumor relapse. J Clin Invest. 2013 Oct; 123(10):4344-58. PMID: 24091326.
      Citations:    
    11. Beckham TH, Cheng JC, Marrison ST, Norris JS, Liu X. Interdiction of sphingolipid metabolism to improve standard cancer therapies. Adv Cancer Res. 2013; 117:1-36. PMID: 23290775.
      Citations:    
    12. Norris JS. The sphingolipid response to cancer therapy. Adv Cancer Res. 2013; 117:xiii-xvii. PMID: 23290783.
      Citations:    
    13. Beckham TH, Lu P, Jones EE, Marrison T, Lewis CS, Cheng JC, Ramshesh VK, Beeson G, Beeson CC, Drake RR, Bielawska A, Bielawski J, Szulc ZM, Ogretmen B, Norris JS, Liu X. LCL124, a cationic analog of ceramide, selectively induces pancreatic cancer cell death by accumulating in mitochondria. J Pharmacol Exp Ther. 2013 Jan; 344(1):167-78. PMID: 23086228.
      Citations:    
    14. Murali AK, Norris JS. Differential expression of epithelial and mesenchymal proteins in a panel of prostate cancer cell lines. J Urol. 2012 Aug; 188(2):632-8. PMID: 22704442.
      Citations:    
    15. Sun H, Liu Y, Bu D, Liu X, Norris JS, Xiao S. Efficient growth suppression and apoptosis in human laryngeal carcinoma cell line HEP-2 induced by an adeno-associated virus expressing human FAS ligand. Head Neck. 2012 Nov; 34(11):1628-33. PMID: 22267220.
      Citations:    
    16. Wang L, Chen W, Feng Y, Ren Y, Gu Z, Chen H, Wang H, Thomas MJ, Zhang B, Berquin IM, Li Y, Wu J, Zhang H, Song Y, Liu X, Norris JS, Wang S, Du P, Shen J, Wang N, Yang Y, Wang W, Feng L, Ratledge C, Zhang H, Chen YQ. Genome characterization of the oleaginous fungus Mortierella alpina. PLoS One. 2011; 6(12):e28319. PMID: 22174787.
      Citations:    
    17. Pandruvada SN, Yuvaraj S, Liu X, Sundaram K, Shanmugarajan S, Ries WL, Norris JS, London SD, Reddy SV. Role of CXC chemokine ligand 13 in oral squamous cell carcinoma associated osteolysis in athymic mice. Int J Cancer. 2010 May 15; 126(10):2319-29. PMID: 19816883.
      Citations:    
    18. Beckham TH, Elojeimy S, Cheng JC, Turner LS, Hoffman SR, Norris JS, Liu X. Targeting sphingolipid metabolism in head and neck cancer: rational therapeutic potentials. Expert Opin Ther Targets. 2010 May; 14(5):529-39. PMID: 20334489.
      Citations:    
    19. Sauane M, Su ZZ, Dash R, Liu X, Norris JS, Sarkar D, Lee SG, Allegood JC, Dent P, Spiegel S, Fisher PB. Ceramide plays a prominent role in MDA-7/IL-24-induced cancer-specific apoptosis. J Cell Physiol. 2010 Mar; 222(3):546-55. PMID: 19937735.
      Citations:    
    20. Liu X, Cheng JC, Turner LS, Elojeimy S, Beckham TH, Bielawska A, Keane TE, Hannun YA, Norris JS. Acid ceramidase upregulation in prostate cancer: role in tumor development and implications for therapy. Expert Opin Ther Targets. 2009 Dec; 13(12):1449-58. PMID: 19874262.
      Citations:    
    21. Yuvaraj S, Griffin AC, Sundaram K, Kirkwood KL, Norris JS, Reddy SV. A novel function of CXCL13 to stimulate RANK ligand expression in oral squamous cell carcinoma cells. Mol Cancer Res. 2009 Aug; 7(8):1399-407. PMID: 19671684.
      Citations:    
    22. Mahdy AE, Cheng JC, Li J, Elojeimy S, Meacham WD, Turner LS, Bai A, Gault CR, McPherson AS, Garcia N, Beckham TH, Saad A, Bielawska A, Bielawski J, Hannun YA, Keane TE, Taha MI, Hammouda HM, Norris JS, Liu X. Acid ceramidase upregulation in prostate cancer cells confers resistance to radiation: AC inhibition, a potential radiosensitizer. Mol Ther. 2009 Mar; 17(3):430-8. PMID: 19107118.
      Citations:    
    23. Zeidan YH, Jenkins RW, Korman JB, Liu X, Obeid LM, Norris JS, Hannun YA. Molecular targeting of acid ceramidase: implications to cancer therapy. Curr Drug Targets. 2008 Aug; 9(8):653-61. PMID: 18691012.
      Citations:    
    24. Liu X, Elojeimy S, Turner LS, Mahdy AE, Zeidan YH, Bielawska A, Bielawski J, Dong JY, El-Zawahry AM, Guo GW, Hannun YA, Holman DH, Rubinchik S, Szulc Z, Keane TE, Tavassoli M, Norris JS. Acid ceramidase inhibition: a novel target for cancer therapy. Front Biosci. 2008 Jan 01; 13:2293-8. PMID: 17981711.
      Citations:    
    25. Ghatak S, Hascall VC, Berger FG, Penas MM, Davis C, Jabari E, He X, Norris JS, Dang Y, Markwald RR, Misra S. Tissue-specific shRNA delivery: a novel approach for gene therapy in cancer. Connect Tissue Res. 2008; 49(3):265-9. PMID: 18661357.
      Citations:    
    26. Klanrit P, Flinterman MB, Odell EW, Melino G, Killick R, Norris JS, Tavassoli M. Specific isoforms of p73 control the induction of cell death induced by the viral proteins, E1A or apoptin. Cell Cycle. 2008 Jan 15; 7(2):205-15. PMID: 18256531.
      Citations:    
    27. Szulc ZM, Mayroo N, Bai A, Bielawski J, Liu X, Norris JS, Hannun YA, Bielawska A. Novel analogs of D-e-MAPP and B13. Part 1: synthesis and evaluation as potential anticancer agents. Bioorg Med Chem. 2008 Jan 15; 16(2):1015-31. PMID: 17869115.
      Citations:    
    28. Bielawska A, Bielawski J, Szulc ZM, Mayroo N, Liu X, Bai A, Elojeimy S, Rembiesa B, Pierce J, Norris JS, Hannun YA. Novel analogs of D-e-MAPP and B13. Part 2: signature effects on bioactive sphingolipids. Bioorg Med Chem. 2008 Jan 15; 16(2):1032-45. PMID: 17881234.
      Citations:    
    29. Karahatay S, Thomas K, Koybasi S, Senkal CE, Elojeimy S, Liu X, Bielawski J, Day TA, Gillespie MB, Sinha D, Norris JS, Hannun YA, Ogretmen B. Clinical relevance of ceramide metabolism in the pathogenesis of human head and neck squamous cell carcinoma (HNSCC): attenuation of C(18)-ceramide in HNSCC tumors correlates with lymphovascular invasion and nodal metastasis. Cancer Lett. 2007 Oct 18; 256(1):101-11. PMID: 17619081.
      Citations:    
    30. Saad AF, Meacham WD, Bai A, Anelli V, Elojeimy S, Mahdy AE, Turner LS, Cheng J, Bielawska A, Bielawski J, Keane TE, Obeid LM, Hannun YA, Norris JS, Liu X. The functional effects of acid ceramidase overexpression in prostate cancer progression and resistance to chemotherapy. . 2007 Sep; 6(9):1455-60. PMID: 17881906.
      Citations:    
    31. Holman DH, Turner LS, El-Zawahry A, Elojeimy S, Liu X, Bielawski J, Szulc ZM, Norris K, Zeidan YH, Hannun YA, Bielawska A, Norris JS. Lysosomotropic acid ceramidase inhibitor induces apoptosis in prostate cancer cells. Cancer Chemother Pharmacol. 2008 Feb; 61(2):231-42. PMID: 17429631.
      Citations:    
    32. Elojeimy S, Liu X, McKillop JC, El-Zawahry AM, Holman DH, Cheng JY, Meacham WD, Mahdy AE, Saad AF, Turner LS, Cheng J, A Day T, Dong JY, Bielawska A, Hannun YA, Norris JS. Role of acid ceramidase in resistance to FasL: therapeutic approaches based on acid ceramidase inhibitors and FasL gene therapy. Mol Ther. 2007 Jul; 15(7):1259-63. PMID: 17426710.
      Citations:    
    33. Guinn BA, Kasahara N, Farzaneh F, Habib NA, Norris JS, Deisseroth AB. Recent advances and current challenges in tumor immunology and immunotherapy. Mol Ther. 2007 Jun; 15(6):1065-71. PMID: 17375068.
      Citations:    
    34. Liu X, Zeidan YH, Elojeimy S, Holman DH, El-Zawahry AM, Guo GW, Bielawska A, Bielawski J, Szulc Z, Rubinchik S, Dong JY, Keane TE, Tavassoli M, Hannun YA, Norris JS. Involvement of sphingolipids in apoptin-induced cell killing. Mol Ther. 2006 Nov; 14(5):627-36. PMID: 16926120.
      Citations:    
    35. Elojeimy S, Holman DH, Liu X, El-Zawahry A, Villani M, Cheng JC, Mahdy A, Zeidan Y, Bielwaska A, Hannun YA, Norris JS. New insights on the use of desipramine as an inhibitor for acid ceramidase. FEBS Lett. 2006 Aug 21; 580(19):4751-6. PMID: 16901483.
      Citations:    
    36. Liu X, Elojeimy S, El-Zawahry AM, Holman DH, Bielawska A, Bielawski J, Rubinchik S, Guo GW, Dong JY, Keane T, Hannun YA, Tavassoli M, Norris JS. Modulation of ceramide metabolism enhances viral protein apoptin's cytotoxicity in prostate cancer. Mol Ther. 2006 Nov; 14(5):637-46. PMID: 16887394.
      Citations:    
    37. Zeidan YH, Pettus BJ, Elojeimy S, Taha T, Obeid LM, Kawamori T, Norris JS, Hannun YA. Acid ceramidase but not acid sphingomyelinase is required for tumor necrosis factor-{alpha}-induced PGE2 production. J Biol Chem. 2006 Aug 25; 281(34):24695-703. PMID: 16803890.
      Citations:    
    38. Norris JS, Bielawska A, Day T, El-Zawahri A, ElOjeimy S, Hannun Y, Holman D, Hyer M, Landon C, Lowe S, Dong JY, McKillop J, Norris K, Obeid L, Rubinchik S, Tavassoli M, Tomlinson S, Voelkel-Johnson C, Liu X. Combined therapeutic use of AdGFPFasL and small molecule inhibitors of ceramide metabolism in prostate and head and neck cancers: a status report. Cancer Gene Ther. 2006 Dec; 13(12):1045-51. PMID: 16763610.
      Citations:    
    39. Norris JS, Norris KL, Holman DH, El-Zawahry A, Keane TE, Dong JY, Tavassoli M. The present and future for gene and viral therapy of directly accessible prostate and squamous cell cancers of the head and neck. Future Oncol. 2005 Feb; 1(1):115-23. PMID: 16555981.
      Citations:    
    40. Sudarshan S, Holman DH, Hyer ML, Voelkel-Johnson C, Dong JY, Norris JS. In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancer. Cancer Gene Ther. 2005 Jan; 12(1):12-8. PMID: 15514684.
      Citations:    
    41. Imai M, Hwang HY, Norris JS, Tomlinson S. The effect of dexamethasone on human mucin 1 expression and antibody-dependent complement sensitivity in a prostate cancer cell line in vitro and in vivo. Immunology. 2004 Mar; 111(3):291-7. PMID: 15009429.
      Citations:    
    42. Rubinchik S, Yu H, Woraratanadharm J, Voelkel-Johnson C, Norris JS, Dong JY. Enhanced apoptosis of glioma cell lines is achieved by co-delivering FasL-GFP and TRAIL with a complex Ad5 vector. Cancer Gene Ther. 2003 Nov; 10(11):814-22. PMID: 14605667.
      Citations:    
    43. Fanzo JC, Lynch MP, Phee H, Hyer M, Cremesti A, Grassme H, Norris JS, Coggeshall KM, Rueda BR, Pernis AB, Kolesnick R, Gulbins E. CD95 rapidly clusters in cells of diverse origins. . 2003 Jul-Aug; 2(4):392-5. PMID: 14508111.
      Citations:    
    44. Schofield DA, Westwater C, Hoel BD, Werner PA, Norris JS, Schmidt MG. Development of a thermally regulated broad-spectrum promoter system for use in pathogenic gram-positive species. Appl Environ Microbiol. 2003 Jun; 69(6):3385-92. PMID: 12788740.
      Citations:    
    45. Westwater C, Kasman LM, Schofield DA, Werner PA, Dolan JW, Schmidt MG, Norris JS. Use of genetically engineered phage to deliver antimicrobial agents to bacteria: an alternative therapy for treatment of bacterial infections. Antimicrob Agents Chemother. 2003 Apr; 47(4):1301-7. PMID: 12654662.
      Citations:    
    46. Hyer ML, Sudarshan S, Schwartz DA, Hannun Y, Dong JY, Norris JS. Quantification and characterization of the bystander effect in prostate cancer cells following adenovirus-mediated FasL expression. Cancer Gene Ther. 2003 Apr; 10(4):330-9. PMID: 12679806.
      Citations:    
    47. Schofield DA, Westwater C, Dolan JW, Norris JS, Schmidt MG. Doc-mediated cell killing in Shigella flexneri using a C1/LacI controlled expression system. FEMS Microbiol Lett. 2002 Oct 08; 215(2):237-42. PMID: 12399040.
      Citations:    
    48. Hyer ML, Sudarshan S, Kim Y, Reed JC, Dong JY, Schwartz DA, Norris JS. Downregulation of c-FLIP sensitizes DU145 prostate cancer cells to Fas-mediated apoptosis. . 2002 Jul-Aug; 1(4):401-6. PMID: 12432255.
      Citations:    
    49. Schofield DA, Westwater C, Dolan JW, Norris JS, Schmidt MG. Tight regulation and modulation via a C1-regulated promoter in Escherichia coli and Pseudomonas aeruginosa. Curr Microbiol. 2002 Jun; 44(6):425-30. PMID: 12000993.
      Citations:    
    50. Kasman LM, Kasman A, Westwater C, Dolan J, Schmidt MG, Norris JS. Overcoming the phage replication threshold: a mathematical model with implications for phage therapy. J Virol. 2002 Jun; 76(11):5557-64. PMID: 11991984.
      Citations:    
    51. Westwater C, Schofield DA, Schmidt MG, Norris JS, Dolan JW. Development of a P1 phagemid system for the delivery of DNA into Gram-negative bacteria. Microbiology (Reading). 2002 Apr; 148(Pt 4):943-950. PMID: 11932441.
      Citations:    
    52. Honda T, Kagawa S, Spurgers KB, Gjertsen BT, Roth JA, Fang B, Lowe SL, Norris JS, Meyn RE, McDonnell TJ. A recombinant adenovirus expressing wild-type Bax induces apoptosis in prostate cancer cells independently of their Bcl-2 status and androgen sensitivity. . 2002 Mar-Apr; 1(2):163-7. PMID: 12170776.
      Citations:    
    53. Voelkel-Johnson C, King DL, Norris JS. Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL. Cancer Gene Ther. 2002 Feb; 9(2):164-72. PMID: 11857034.
      Citations:    
    54. Huang Y, Fang Y, Dziadyk JM, Norris JS, Fan W. The possible correlation between activation of NF-kappaB/IkappaB pathway and the susceptibility of tumor cells to paclitaxel-induced apoptosis. Oncol Res. 2002; 13(2):113-22. PMID: 12392159.
      Citations:    
    55. Rubinchik S, Norris JS, Dong JY. Construction, purification and characterization of adenovirus vectors expressing apoptosis-inducing transgenes. Methods Enzymol. 2002; 346:529-47. PMID: 11883089.
      Citations:    
    56. Norris JS, Hyer ML, Voelkel-Johnson C, Lowe SL, Rubinchik S, Dong JY. The use of Fas Ligand, TRAIL and Bax in gene therapy of prostate cancer. Curr Gene Ther. 2001 May; 1(1):123-36. PMID: 12109135.
      Citations:    
    Norris's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (332)
    Explore
    _
    Co-Authors (28)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _